Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma

Irene M. Ghobrial*, Chia Jen Liu, Oksana Zavidij, Abdel K. Azab, Rachid Baz, Jacob P. Laubach, Yuji Mishima, Philippe Armand, Nikhil C. Munshi, Frank Basile, Michael Constantine, James Vredenburgh, Adam Boruchov, Pamela Crilley, Patrick M. Henrick, Kalvis T.V. Hornburg, Houry Leblebjian, Stacey Chuma, Kaitlen Reyes, Kimberly NoonanDiane Warren, Robert Schlossman, Claudia Paba-Prada, Kenneth C. Anderson, Edie Weller, Lorenzo Trippa, Kenneth Shain, Paul G. Richardson

*此作品的通信作者

研究成果: Article同行評審

44 引文 斯高帕斯(Scopus)

指紋

深入研究「Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma」主題。共同形成了獨特的指紋。

Keyphrases

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science